Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsGuy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
Life of this patent
Estimating the term…
Abstract
The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
Claims8
An immunogenic composition comprising:
- (a) a fusion protein comprising a carrier protein coupled to a human rhinovirus (HRV) peptide, said HRV peptide comprising no more than 20 amino acids from the N terminus of HRV VP4 and comprising a sequence selected from SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7;
- and
- (b) a pharmaceutically acceptable diluent, excipient or carrier.
A fusion protein comprising a carrier protein coupled to a HRV peptide, said HRV peptide comprising no more than 20 amino acids from the N terminus of VP4 and comprising a sequence selected from SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7.
A method for preparing an immunogenic composition which method comprises combining:
- a fusion protein comprising a carrier protein coupled to a human rhinovirus (HRV) peptide, said HRV peptide comprising no more than 20 amino acids from the N terminus of HRV VP4 and comprising a sequence selected from SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, and a pharmaceutically acceptable diluent, excipient, or carrier.
Dependencies are inferred from the claim text.